Piper Sandler Rates Illumina (ILMN) buy, $200 Price Target

Piper Sandler reaffirmed its buy rating on Illumina, Inc. on July 1, 2026, setting a $200 price target for the genetic analysis tools provider, a 13.75% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 8:00 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Piper Sandler rated Illumina, Inc. ($ILMN) "buy" with a $200 price target on July 1, 2026.

Since the rating, $ILMN is up 2.1% after 1 week, up 11.5% after 1 month and up 42.8% to date (from the $183.89 close on Jul 1, 2026).

ILMN Illumina, Inc.

$262.54 +95.41% year to date

Daily close · Oct 16, 2026

Key Points

Piper Sandler analyst David Westenberg reaffirmed a buy rating on Illumina, Inc. (NasdaqGS: ILMN) with a $200 price target on July 1, 2026.
Piper Sandler's $200 price target implies 13.75% upside from Illumina, Inc.'s ($ILMN) current $175.83 share price.
Illumina shares trade around $175.83, well below their 52-week peak of $250.06 and above their low of $88.00.
Wall Street maintains a general buy view on Illumina, backed by a mean target price of $202.65 across twenty analysts.

Get $ILMN trade alerts by text

We text you when insiders, Congress or big funds trade $ILMN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Illumina, Inc. alert may contain errors. Disclosures

Piper Sandler Updates Its View on Illumina Stock

Piper Sandler analyst David Westenberg reaffirmed a buy rating on Illumina, Inc. (NasdaqGS: ILMN) on July 1, 2026, keeping a $200 price target on the shares. The decision highlights steady confidence from the firm as the genetic testing company navigates market shifts and evaluates its pipeline for genomic solutions. The advisory comes as Wall Street watches how diagnostic firms balance research spending against shifting healthcare demand.

Analyst rating track record

Piper Sandler vs. the S&P 500

YTD return -11.77% hypothetical

All-time return +31.96% S&P 500 +36.53%

vs. S&P 500 -4.57% behind the index

Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.

12-month forecast

$ILMN price target

Illumina, Inc. daily closes and this analyst's $200 target. Not advice.

Recent Stock Price Trends for Illumina

Illumina shares trade around $175.83, positioning the company well away from its 52-week low of $88.00 and its high of $250.06. The stock's valuation reflects a forward P/E of roughly 39.1, based on expected earnings over the next year. With a beta of 1.47, the equity tends to swing more sharply than the broader market as investors reassess life-science instrument makers.

Earnings and Financial Health

Illumina brought in $4.49 billion in revenue over its most recent annual period, showing a growth rate of 9.4%. The company posted earnings of $5.37 per share, accompanied by a net profit margin of 18.3% and a return on equity of 32.3%. The next corporate earnings update is scheduled for October 29, 2026, when management will give fresh details on instrument consumables and genetic sequencing kits.

Wall Street Analyst Coverage

Several other firms have updated their outlooks on Illumina in recent weeks. On October 13, 2026, TD Cowen maintained a hold rating while lifting its target to $270.00 from $210.00. Barclays kept an underweight rating on October 7, 2026, with a target of $200.00. RBC Capital kept an outperform rating on October 5, 2026, raising its target to $310.00. Guggenheim maintained a buy rating on October 1, 2026, raising its target to $305.00. Leerink Partners kept an outperform rating on September 29, 2026, lifting its target to $300.00. Piper Sandler maintained an overweight rating on September 28, 2026, with a $305.00 target. UBS upgraded the stock to a buy on September 9, 2026, setting a $260.00 target. Argus Research maintained a buy rating on September 3, 2026, with a $235.00 target. Altogether, twenty analysts track the firm, producing a consensus buy recommendation and a mean price target of $202.65.

Inside Illumina's Genomic Business

Headquartered in San Diego, California, Illumina builds sequencing and array-based tools for genetic analysis. Its products help academic labs, hospitals, and biotech companies decode DNA, study RNA, and run prenatal screenings. The company's technology is a staple of modern genomic research, underpinning studies in rare diseases and oncology.

What to Watch at Illumina, Inc.

Investors will look toward the company's next earnings report scheduled for October 29, 2026, to gauge demand for sequencing consumables and flow cells. Rating updates from firms like Piper Sandler and TD Cowen will continue to shape market sentiment in the healthcare sector. As always, analyst targets reflect shifting long-term expectations rather than immediate trading signals.